Post-RT Urinary Incontinence and Stricture

  • Gillian Stearns
  • Laura LeddyEmail author


Radiotherapy (RT) is an effective treatment for localized prostate cancer; however, post-treatment urinary complications differ from radical surgery. Prostate RT results in a higher prevalence of overactive bladder (OAB), detrusor overactivity (DO), and urgency urinary incontinence. These lower urinary tract symptoms can be transient or lasting. Pharmacologic therapy effectively treats post-RT OAB and urgency urinary incontinence. Post-RT urethral stricture disease can occur after all modalities of prostate RT. The incidence varies by modality and time from treatment. Endoscopic and surgical therapies are effective in treating post-RT urethral stricture disease. This chapter discusses the pathophysiology, prevalence, and evaluation of post-RT urinary incontinence and post-RT urethral stricture disease. The medical and surgical management options for these entities are reviewed.


Prostate cancer Radiation Incontinence Urethra Stricture 


  1. 1.
    Sriprasad S, Feneley MR, Thompson PM. History of prostate cancer treatment. Surg Oncol. 2009;18:185.CrossRefPubMedGoogle Scholar
  2. 2.
    Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106.CrossRefPubMedGoogle Scholar
  3. 3.
    Thiruchelvam, N., Cruz, F., Kirby, M., Tubaro, A., Chapple, C. R. and Sievert, K.-D. (2015), A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. BJU International. doi:10.1111/bju.13078Google Scholar
  4. 4.
    Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167.CrossRefPubMedGoogle Scholar
  5. 5.
    Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology. 2003;62:28.CrossRefPubMedGoogle Scholar
  6. 6.
    Antonakopoulos GN, Hicks RM, Berry RJ. The subcellular basis of damage to the human urinary bladder induced by irradiation. J Pathol. 1984;143:103.CrossRefPubMedGoogle Scholar
  7. 7.
    Marks LB, Carroll PR, Dugan TC, et al. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1257.CrossRefPubMedGoogle Scholar
  8. 8.
    Lundbeck F, Ulso N, Overgaard J. Cystometric evaluation of early and late irradiation damage to the mouse urinary bladder. Radiother Oncol. 1989;15:383.CrossRefPubMedGoogle Scholar
  9. 9.
    Choo R, Do V, Herschorn S, et al. Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;53:290.CrossRefPubMedGoogle Scholar
  10. 10.
    Markland AD, Goode PS, Redden DT, et al. Prevalence of urinary incontinence in men: results from the national health and nutrition examination survey. J Urol. 2010;184:1022.CrossRefPubMedGoogle Scholar
  11. 11.
    Litwin MS. Health related quality of life in older men without prostate cancer. J Urol. 1999;161:1180.CrossRefPubMedGoogle Scholar
  12. 12.
    Resnick MJ, Barocas DA, Morgans AK, et al. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer. 2014;120:1263.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306.CrossRefPubMedGoogle Scholar
  14. 14.
    Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250.CrossRefPubMedGoogle Scholar
  16. 16.
    Talcott JA, Clark JA, Stark PC, et al. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol. 2001;166:494.CrossRefPubMedGoogle Scholar
  17. 17.
    Blaivas JG, Weiss JP, Jones M. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer. BJU Int. 2006;98:1233.CrossRefPubMedGoogle Scholar
  18. 18.
    Chen AB, D’Amico AV, Neville BA, et al. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24:5298.CrossRefPubMedGoogle Scholar
  19. 19.
    Jiang R, Tomaszewski JJ, Ward KC, et al. The burden of overtreatment: comparison of toxicity between single and combined modality radiation therapy among low risk prostate cancer patients. Can J Urol. 2015;22:7648.PubMedGoogle Scholar
  20. 20.
    Gupta S, Peterson AC. Stress urinary incontinence in the prostate cancer survivor. Curr Opin Urol. 2014;24:395.CrossRefPubMedGoogle Scholar
  21. 21.
    Jeong SJ, Kim HJ, Lee YJ, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean J Urol. 2012;53:342.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Collins CW, Winters JC, American Urological A, et al. AUA/SUFU adult urodynamics guideline: a clinical review. Urol Clin North Am. 2014;41:353.CrossRefPubMedGoogle Scholar
  23. 23.
    Elshaikh MA, Ulchaker JC, Reddy CA, et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys. 2005;62:164.CrossRefPubMedGoogle Scholar
  24. 24.
    Zelefsky MJ, Ginor RX, Fuks Z, et al. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:567.CrossRefPubMedGoogle Scholar
  25. 25.
    Bittner N, Merrick GS, Brammer S, et al. Role of trospium chloride in brachytherapy-related detrusor overactivity. Urology. 2008;71:460.CrossRefPubMedGoogle Scholar
  26. 26.
    Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190:1320.CrossRefPubMedGoogle Scholar
  27. 27.
    Otsuki H, Kosaka T, Nakamura K, et al. beta3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45:53.CrossRefPubMedGoogle Scholar
  28. 28.
    Crew JP, Jephcott CR, Reynard JM. Radiation-induced haemorrhagic cystitis. Eur Urol. 2001; 40:111.CrossRefPubMedGoogle Scholar
  29. 29.
    deVries CR, Freiha FS. Hemorrhagic cystitis: a review. J Urol. 1990;143:1.PubMedGoogle Scholar
  30. 30.
    Tibbs MK. Wound healing following radiation therapy: a review. Radiother Oncol. 1997;42:99.CrossRefPubMedGoogle Scholar
  31. 31.
    Herschorn S, Elliott S, Coburn M, et al. SIU/ICUD Consultation on Urethral Strictures: Posterior urethral stenosis after treatment of prostate cancer. Urology. 2014;83:S59.CrossRefPubMedGoogle Scholar
  32. 32.
    Elliott SP, Meng MV, Elkin EP, et al. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol. 2007;178:529.CrossRefPubMedGoogle Scholar
  33. 33.
    Allen ZA, Merrick GS, Butler WM, et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys. 2005;62:981.CrossRefPubMedGoogle Scholar
  34. 34.
    Leapman MS, Stock RG, Stone NN, et al. Findings at cystoscopy performed for cause after prostate brachytherapy. Urology. 2014;83:1350.CrossRefPubMedGoogle Scholar
  35. 35.
    Merrick GS, Butler WM, Wallner KE, et al. Risk factors for the development of prostate brachytherapy related urethral strictures. J Urol. 2006;175:1376.CrossRefPubMedGoogle Scholar
  36. 36.
    Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124.CrossRefPubMedGoogle Scholar
  37. 37.
    Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:65.CrossRefPubMedGoogle Scholar
  38. 38.
    Astrom L, Pedersen D, Mercke C, et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol. 2005;74:157.CrossRefPubMedGoogle Scholar
  39. 39.
    Sullivan L, Williams SG, Tai KH, et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol. 2009;91:232.CrossRefPubMedGoogle Scholar
  40. 40.
    Hindson BR, Millar JL, Matheson B. Urethral strictures following high-dose-rate brachytherapy for prostate cancer: analysis of risk factors. Brachytherapy. 2013;12:50.CrossRefPubMedGoogle Scholar
  41. 41.
    McDonald AM, Baker CB, Popple RA et al. Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy. Pract Radiat Oncol. doi:10.1016/j.prro.2015.02.010.Google Scholar
  42. 42.
    Lawton CA, Bae K, Pilepich M, et al. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys. 2008;70:437.CrossRefPubMedGoogle Scholar
  43. 43.
    Gardner BG, Zietman AL, Shipley WU, et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002;167:123.CrossRefPubMedGoogle Scholar
  44. 44.
    Chism DB, Horwitz EM, Hanlon AL, et al. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys. 2003;55:71.CrossRefPubMedGoogle Scholar
  45. 45.
    Macdonald OK, Lee RJ, Snow G, et al. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer. Urology. 2007;69:295.CrossRefPubMedGoogle Scholar
  46. 46.
    Cozzarini C, Fiorino C, Di Muzio N, et al. Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study. Radiother Oncol. 2008;88:26.CrossRefPubMedGoogle Scholar
  47. 47.
    Chi AC, Han J, Gonzalez CM. Urethral strictures and the cancer survivor. Curr Opin Urol. 2014;24:415.CrossRefPubMedGoogle Scholar
  48. 48.
    Erickson BA, McAninch JW, Eisenberg ML, et al. Management for prostate cancer treatment related posterior urethral and bladder neck stenosis with stents. J Urol. 2011;185:198.CrossRefPubMedGoogle Scholar
  49. 49.
    Glass AS, McAninch JW, Zaid UB, et al. Urethroplasty after radiation therapy for prostate cancer. Urology. 2012;79:1402.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Hofer MD, Zhao LC, Morey AF, et al. Outcomes after urethroplasty for radiotherapy induced bulbomembranous urethral stricture disease. J Urol. 2014;191:1307.CrossRefPubMedGoogle Scholar
  51. 51.
    Palmer DA, Buckley JC, Zinman LN, et al. Urethroplasty for high risk, long segment urethral strictures with ventral buccal mucosa graft and gracilis muscle flap. J Urol. 2015;193:902.CrossRefPubMedGoogle Scholar
  52. 52.
    Bates, A. S., Martin, R. M. and Terry, T. R. (2015), Complications following artificial urinary sphincter placement after radical prostatectomy and radiotherapy: a meta-analysis. BJU International, 116: 623–633. doi:10.1111/bju.13048Google Scholar
  53. 53.
    Brant WO, Erickson BA, Elliott SP, et al. Risk factors for erosion of artificial urinary sphincters: a multicenter prospective study. Urology. 2014;84:934.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of UrologyUniversity of VermontBurlingtonUSA
  2. 2.Department of Surgery, Urology ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations